T. Rowe Price Associates
TMDX icon

T. Rowe Price Associates’s Transmedics TMDX Stock Holding History

T. Rowe Price Associates’s Portfolio TMDX Stock Details TMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.06M Sell
46,028
-300,655
-87% -$25.4M ﹤0.01% 1803
2026
Q1 		$34.5M Sell
346,683
-223,287
-39% -$29.1M ﹤0.01% 887
2025
Q4 		$69.3M Buy
569,970
+171,810
+43% +$21.6M 0.01% 714
2025
Q3 		$44.7M Buy
398,160
+260,270
+189% +$30.5M ﹤0.01% 834
2025
Q2 		$18.5M Buy
137,890
+2,192
+2% +$241K ﹤0.01% 977
2025
Q1 		$9.13M Sell
135,698
-122,947
-48% -$8.46M ﹤0.01% 1131
2024
Q4 		$16.1M Sell
258,645
-34,821
-12% -$3.24M ﹤0.01% 1039
2024
Q3 		$46.1M Sell
293,466
-36,968
-11% -$5.7M 0.01% 778
2024
Q2 		$49.8M Buy
330,434
+33,110
+11% +$3.97M 0.01% 727
2024
Q1 		$22M Buy
297,324
+22,223
+8% +$1.83M ﹤0.01% 955
2023
Q4 		$21.7M Buy
275,101
+153,861
+127% +$9.28M ﹤0.01% 935
2023
Q3 		$6.64M Buy
121,240
+105,319
+662% +$7.58M ﹤0.01% 1131
2023
Q2 		$1.34M Buy
15,921
+880
+6% +$67.4K ﹤0.01% 1652
2023
Q1 		$1.14M Buy
15,041
+529
+4% +$36.6K ﹤0.01% 1724
2022
Q4 		$896K Buy
14,512
+288
+2% +$15.3K ﹤0.01% 1830
2022
Q3 		$594K Buy
14,224
+5,803
+69% +$252K ﹤0.01% 2042
2022
Q2 		$265K Buy
8,421
+171
+2% +$4.56K ﹤0.01% 2495
2022
Q1 		$222K Sell
8,250
-178,013
-96% -$3.19M ﹤0.01% 2676
2021
Q4 		$3.57M Buy
+186,263
New +$4.67M ﹤0.01% 1550
2021
Q1 		– Sell
-336,789
Closed -$6.7M – 2871
2020
Q4 		$6.7M Sell
336,789
-89,442
-21% -$1.32M ﹤0.01% 1403
2020
Q3 		$5.87M Buy
426,231
+185
+0% +$3.17K ﹤0.01% 1385
2020
Q2 		$7.63M Sell
426,046
-33,080
-7% -$517K ﹤0.01% 1337
2020
Q1 		$5.55M Sell
459,126
-62,495
-12% -$1.05M ﹤0.01% 1329
2019
Q4 		$9.92M Buy
+521,621
New +$9.58M ﹤0.01% 1313

Other funds holding TMDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

T. Rowe Price Associates's TMDX Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Transmedics (TMDX) stake by 87% in Q2 2026, selling an estimated $25.4M and leaving 46,028 shares worth $3.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1803.

T. Rowe Price Associates first reported a position in TMDX in Q4 2019 and has held it in 24 quarters since. The position peaked at $69.3M in Q4 2025. 374 funds tracked by Wall St. Rank hold TMDX as of Q2 2026.

  • T. Rowe Price Associates held 46,028 shares of Transmedics worth $3.06M as of Q2 2026.
  • T. Rowe Price Associates sold 300,655 Transmedics shares in Q2 2026, an estimated $25.4M.
  • Transmedics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1803 holding.
  • T. Rowe Price Associates first reported a position in Transmedics in Q4 2019 and has held it in 24 quarters since.
  • T. Rowe Price Associates's Transmedics position peaked at $69.3M in Q4 2025.
  • 374 funds tracked by Wall St. Rank held Transmedics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.